Researchers Find “Biological Rationale” for New Kind of Mesothelioma Treatment, According to Surviving Mesothelioma

Share Article

A new study suggests that enzyme-blockers being tested for other cancers may offer a new way to treat malignant pleural mesothelioma.

Enzyme Blockers May Be New Way to Treat Mesothelioma

This could be a tremendous innovation for patients

(PRWEB)November 12, 2015

Doctors in New York are hopeful that new research on BAP1 gene mutations and elevated levels of an enzyme called EZH2 will open the door to a targeted new treatment for mesothelioma. Surviving Mesothelioma has just posted an article on their new study. Click here to read it now.

Scientists at Memorial Sloan Kettering Cancer Center in New York recently found that mesothelioma-infected mice with BAP1 gene mutations had higher levels of the enzyme EZH2 and faster-growing mesothelioma tumors.

In the wake of the study in Nature Medicine, Memorial Sloan Kettering mesothelioma specialist Marjorie Zauderer, MD, says she is hopeful that new drugs designed to block EZH2 may help mesothelioma patients.

“Now that there’s a biological rationale for why these drugs would work in mesothelioma, this could be a tremendous innovation for patients,” says Dr. Zauderer.

“It is always very encouraging when we get news of a potential innovation like the use of EZH2-blockers to treat mesothelioma,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. “The more we learn about this rare cancer, the greater the chance that scientists will eventually find a way to cure it.”

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.